Apr 23,2021

DarioHealth, MediOrbis partner on virtual care for diabetes

Digital therapeutics company DarioHealth is teaming up with MediOrbis to launch a new virtual care initiative for diabetes patients. Eligible Medicare members who have diabetes can receive virtual care to help manage their conditions, including telehealth delivered by MediOrbis and remote patient monitoring through DarioHealth's artificial-intelligence-powered digital chronic care platform under their existing Medicare benefit, the companies announced.

COLLABORATION PARTNERSHIP

#product & service

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 27,2021

Voluntis and Eisai to collaborate on digital therapeutics for oncology patients

Voluntis, a leader in digital therapeutics, today announced a collaboration agreement with Eisai (Headquarters: Tokyo) to design and develop innovative digital therapeutics (DTx) to support patients treated for cancer as well as a strategic investment from Eisai in Voluntis. By leveraging Voluntis’ Theraxium technology platform, the two companies will collaborate on novel DTx specifically designed for patients and healthcare professionals to support cancer treatment. The partners’ goals are to jointly design and develop new DTx, and evaluate their benefits for patients, caregivers and healthcare professionals. Ultimately, the companies would collaborate on the commercialization of the DTx, once authorized for marketing by regulatory authorities. The new assets will be designed with the intent to be commercialized in the US, Japan and European markets.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 28,2021

Welldoc Granted 20th US Patent, Growing Company’s Platform Solutions

Welldoc®, a trailblazer in digital health that is revolutionizing chronic condition management to help transform lives, today announced that the company’s 20th U.S. patent was granted by the U.S. Patent and Trademark Office on April 13, 2021. The company’s offerings include the award-winning BlueStar® diabetes management solution, which uses digital health to provide a comprehensive platform with education, real-time feedback and an Insulin Adjustment Program. BlueStar is cleared by the U.S. Food and Drug Administration (FDA) for adults with type 1 or type 2 diabetes. The platform is device-agnostic, allowing for seamless integration with a patient’s existing blood glucose meters, pharmacies, labs, and activity and fitness trackers.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
May 12,2021

Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence

Voluntis, a leader in digital therapeutics, today announced that it has received the CE mark for a new version of Oleena featuring expanded clinical intelligence. Oleena is Voluntis’ proprietary digital therapeutic that supports patients in the self-management of their symptoms in combination with a wide range of cancer treatments, while allowing healthcare teams to remotely monitor the progress of the disease. It is based on the Theraxium platform developed by Voluntis, which also serves as the foundation for the digital therapeutics the company is co-developing with pharmaceutical partners.

REGULATORY CE MARK

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 12,2021

Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring App

Tilak Healthcare, a digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases, is launching a pilot program in the US with Novartis for OdySight, Tilak Healthcare’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and Novartis to promote OdySight in the US and Europe following a successful collaboration in France.

PRODUCT

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
May 14,2021

One Drop Receives CE Mark for AI-Powered Blood Glucose Forecasts

One Drop, a leader in precision health solutions for people living with chronic conditions, today announced it has achieved the Conformité Européenne (CE) Mark for its Blood Glucose Prediction Analysis Engine-1 to accurately forecast glucose levels up to eight hours in advance for people living with prediabetes, type 2 diabetes, and gestational diabetes.

REGULATORY CE MARK

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
May 26,2021

One Drop Receives CE Mark, Launches Data-Driven Insights for People Managing High Blood Pressure

One Drop, a leader in precision health solutions for people living with chronic conditions, today announced it has received the Conformité Européenne (CE) Mark for its Blood Pressure Trend and Analysis Engine-1 to generate blood pressure (BP) insights. As part of the One Drop Digital Membership, consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.

REGULATORY CE MARK

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2021

Blue Note Therapeutics Announces Recruitment for Registrational Clinical Trial Studying Effectiveness of Digital Medical Devices in Cancer Patients

Blue Note Therapeutics has announced recruitment for a registrational clinical trial (RCT) to study the effectiveness of two digital, software only, medical devices (SaMD). Both medical devices are anticipated to have an impact on mental and physical health when used adjunctively with multidisciplinary oncology care regimens. The RCT study population will consist of up to 553 patients living with stage I-III breast cancer or stage I-III non-small cell lung cancer. The study will seek to understand and evaluate the overall study outcomes, including impact on mental and physical health.

PRODUCT

#software

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 02,2021

Indian digital therapeutics firm launches COVID-19 recovery programme for diabetic patients

Fitterfly, an India-based digital therapeutics company, has launched a digital recovery programme for diabetic patients who have contracted COVID-19. The company has added in its Diabefly platform an integrated module called the Post COVID-19 Recovery programme. According to a press release, people can "take advantage of the programme from the comfort of their home via calls, chat, virtual group sessions and webinars".

PRODUCT

#mobile app

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 03,2021

BehaVR Partners With Reach’s National “Save Moms” Campaign to Improve Maternal Health in Vulnerable Populations

BehaVR, a digital therapeutics company that aims to liberate people from stress, anxiety and fear though the power of virtual reality, today announced a partnership with Save Moms — the national maternal mortality and morbidity prevention campaign directed by Reach, a 501(c)(3) global social impact organization — in support of expectant mothers in underserved communities. BehaVR will provide NurtureVR, a first-of-its-kind virtual reality program for expectant moms, to 5,000 low-income and otherwise marginalized families, along with a portion of sales proceeds, to support Reach’s efforts to provide maternal healthcare resources and education to expectant moms at higher risk for complications during and after pregnancy.

PRODUCT

#virtual reality

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM